Keywords:
Abdomen, MR, Diagnostic procedure
Authors:
I. Sansoni1, I. Di Giampietro1, C. L. Piccolo1, R. Del Vescovo1, B. Beomonte Zobel2; 1Rome/IT, 2Roma/IT
DOI:
10.1594/ecr2011/C-0231
References
-Bell S,
Kamm MA.
Antibodies to tumour necrosis factor alpha as treatment for Crohn’s disease.
Lancet 2000;355:858–860.
- Targan SR et al.
A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease.
Crohn’s Disease cA2 Study Group.
N Engl J Med 1997;337:1029–1035.
-Maccioni F,
Viscido A,
Broglia L,
et al.
Evaluation of Crohn disease activity with magnetic resonance imaging. Abdom Imaging 2000; 25:219–228.
- Gourtsoyiannis N,
Papanikolaou N,
Grammatikakis J,
Papamastorakis G,
Prassopoulos P,
Roussomoustakaki M.
Assessment of Crohn’s disease activity in the small bowel with MR and conventional enteroclysis: preliminary results. Eur Radiol 2004;14:1017–24.
- Del Vescovo R,
Sansoni I,
Caviglia R,
et al.
Dynamic contrast enhanced magnetic resonance imaging of the terminal ileum: differentiation of activity of Crohn’s disease. Abdom Imaging 2008;33:417–24.
-Grobner T.
Gadolinium—a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006;21:1104–1108.
- Kuo PH,
Kanal E,
Abu-Alfa AK,
Cowper SE.
Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis.
Radiology 2007;242:647–649.
-Kilickesmez O,
Atilla S,
Soylu A,
Tasdelen N,
Bayramoglu S,
Cimilli T,
Gurmen N.
Diffusion-Weighted Imaging of the Rectosigmoid Colon: Preliminary Findings. J Comput Assist Tomogr 2009;33: 863-866 - Kiryu S,
Dodanuki K,
Takao H,
Watanabe M,
Inoue Y,
Takazoe M,
Sahara R,
Unuma K,
Ohtomo K.
Free-Breathing Diffusion-Weighted Imaging for the Assessment of Inflammatory Activity in Crohn’s Disease. Journal Of Magnetic Resonance Imaging 2009;29:880–886